BIIB Biogen Inc.
$217.36▲ +0.10%
Healthcare
Other
After hours
$215.62▼ -0.80%
Sep 14, 5:25 PM ET
Volume 629.9K
Avg Volume (10D) 774.2K
Key Metrics & Fundamentals
Market Cap
$32.12B
P/E Ratio
38.7
Div Yield
–%
52W Range
135.39 - 225.80
% vs 50 MA
3.66%
% vs 200 MA
13.14%
RSI-14
53.2
MACD Histogram
-0.9300
Beta (1Y vs SPY)
0.32
Free Cash Flow
$308.00M
Gross Rev
$2.74B
Gross Profit
$1.96B
EBITDA
$747.20M
COGS
$776.90M
Operating Exp
$1.48B
Operating Income
$482.80M
EBIT
$482.80M
Pretax Income
$132.40M
Net Income
$97.50M
EPS (Diluted)
0.66
Price & Volume History
Loading chart…
Recent News
Biogen Sees Pivotal Pipeline Moment as It Expands Beyond Neurology
MarketBeat · Sep 12, 2026 9:01 PM
Register Now: Limited Seating Remains for HMG Strategy’s Sept. 10 Boston C-Level Technology Leadership Summit
GlobeNewswire · Sep 8, 2026 2:30 PM
Lilly Builds Neuroscience into a New Long-Term Growth Driver
Zacks · Sep 8, 2026 12:27 PM
This Biotech Wins a Big FDA Approval. Why Wall Street Is Shrugging.
Barrons.com · Sep 4, 2026 4:13 PM
Exelixis (EXEL) Up 13.3% Since Last Earnings Report: Can It Continue?
Zacks · Sep 4, 2026 3:30 PM
Why Is Veeva Systems (VEEV) Winning Big In AI For Biopharma?
Simply Wall St. · Sep 4, 2026 4:38 AM
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
GlobeNewswire · Sep 3, 2026 11:30 PM
Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Business Wire · Sep 3, 2026 11:30 PM
Piper Sander Adjusts Biogen Price Target to $245 From $225, Maintains Overweight Rating
MT Newswires · Sep 3, 2026 11:36 AM
Biogen (BIIB) Brings At Home Weekly Alzheimer’s Injection To U.S. Patients
Simply Wall St. · Sep 3, 2026 11:06 AM
Financial Overview - Income Statement
Quarterly
Jun 2026
See BIIB's money flow as a full page
Social Sentiment
Avg +0.60 · 1 posts
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.